DR REDDYS LABORATORIES

LTD

COMPANY BACKGROUND
Dr.Reddys Laboratories Ltd founded in 1984 by
Dr k.Angi Reddy has become Indias second
biggest pharmaceutical company and its
headquartered is in Hyderabad.
It produces and sells active pharmaceutical
ingredients , finished dosages and biologics.
It manufactures ulcer medicines, antibiotics, pain
relievers, antidepressants and cardiovascular
drugs.

COMPANY BACKGROUND
Dr Reddys market its product in approximately
100 countries , focusing on Europe,India,US and
Russia.
The company employed over 8255 personnel,
In 1997 it became the first Indian company to
out-license an original molecule (DRF 2593).

Its revenue for 2006 - 2007 amounted to $ 1.5

billion, an increase of 24.3% of the previous year
. Its net income amounts to $ 216 million.

COMPANY BACKGROUND
ON 11 April 2001, Dr Reddys became the first
pharmaceutical company from Asia Pacific to be
listed on Newyork stock exchange.
The company carries out research and
development in diabetes, cancer, cardiovascular
diseases and bacterial infections.
The company has over 120 medications and 60
active pharmaceutical ingredients for drug
manufacture.

Key personnel
Chairman: Dr. K.Angi
Reddy

CEO: G V Prasad

Dr Reddys laboratories in
European union
In 2006 2007, Dr Reddys generated a revenue
of EUR 80.5 million from Europe , which
accounted for 18% of the companys total
revenue.

Dr Reddys Laboratories in
Germany
In march 2006 Dr.reddys acquired Betapharm
arzneimittel GmbH from 3i for euro 480 million.
Betapharm employs more than 350 personnel
and its turnover amounts to Euro 186 million . It
commands a share of 3.5 % in the German
pharmaceutical market.

Dr.Reddy Laboratory in UK
In March 2002 Dr Reddys acquired BHM
Laboratories ,Beverley, and its wholly owned
subsidiary meridian health care, EURO 14.81
million. Recently Dr. Reddys entered into R & D
and Commercialization agreement with Argenta
Discovery Ltd, for the treatment of COPD

In other European countries

Apart from subsidiaries in Germany and UK ,
Dr.Reddys has agreements in following
European countries.
DENMARK
IRELAND

NETHERLANDS

Factors for success

Controlling the entire value chain
Implementations of efficient new product
development processes

High standard of corporate governance

Controlling the entire value

chain
Dr.Reddys controls the entire supply chain and
offers high quality products at competitive prices
at opportune time . In addition it ensures that
quality is maintained at every stage.

Implementations of efficient new

product development processes

Targeting the streamlining of new product

development process, Dr. Reddys implemented
project racha using Microsoft accelerator for six
sigma. This is helping the company in taking key
decisions to launch the right products in the
market at the appropriate time.

High standard of corporate

governance
Dr.Reddys adherence to high standard of
corporate governance and ethical business
practices has been a key factor to its success. The
mutual trust has ensured greater success for the
company.

Future plans
Having acquired Betapharm, one of the
fastest growing generic companies in Germany
over the past 5 years, Dr.Reddys aims at
leveraging this strategic investment to evolve
into a mid-sized global pharmaceutical company.
Dr.Reddys aims to increase
its revenue
substantially and improve its operating margin.